Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery

Objectives: Ipilimumab (Yervoy), an FDA-approved monoclonal antibody against CTLA-4, is the first treatment proven to improve melanoma survival. This randomized, phase III trial asks whether it can improve recurrence-free and/or overall survival if used in the adjuvant setting.

Key entry or exclusion criteria: Patients must have stage IIIB, IIIC, or IV (M1a or M1b) disease (including recurrent disease) that has been completely resected within the previous 12 weeks.

Locations: 67 sites.

Goal: 1,500 patients.

Study sponsor: Eastern Cooperative Oncology Group in collaboration with the National Cancer Institute.

Links for more information: clinicaltrials.gov/ct2/show/NCT01274338

NIH clinical trials identifier: NCT01274338

Objectives: Ipilimumab (Yervoy), an FDA-approved monoclonal antibody against CTLA-4, is the first treatment proven to improve melanoma survival. This randomized, phase III trial asks whether it can improve recurrence-free and/or overall survival if used in the adjuvant setting.

Key entry or exclusion criteria: Patients must have stage IIIB, IIIC, or IV (M1a or M1b) disease (including recurrent disease) that has been completely resected within the previous 12 weeks.

Locations: 67 sites.

Goal: 1,500 patients.

Study sponsor: Eastern Cooperative Oncology Group in collaboration with the National Cancer Institute.

Links for more information: clinicaltrials.gov/ct2/show/NCT01274338

NIH clinical trials identifier: NCT01274338

Objectives: Ipilimumab (Yervoy), an FDA-approved monoclonal antibody against CTLA-4, is the first treatment proven to improve melanoma survival. This randomized, phase III trial asks whether it can improve recurrence-free and/or overall survival if used in the adjuvant setting.

Key entry or exclusion criteria: Patients must have stage IIIB, IIIC, or IV (M1a or M1b) disease (including recurrent disease) that has been completely resected within the previous 12 weeks.

Locations: 67 sites.

Goal: 1,500 patients.

Study sponsor: Eastern Cooperative Oncology Group in collaboration with the National Cancer Institute.

Links for more information: clinicaltrials.gov/ct2/show/NCT01274338

NIH clinical trials identifier: NCT01274338